GE HealthCare Technologies Inc

GE HealthCare Technologies Inc

GEHC

Get informed when a big investor buys or sells

+ Follow
Market Cap$28.02B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
GE HealthCare Technologies IncGE HealthCare Technologies Inc18.70.23%14%1.41.2

Earnings Call Q1 2026

April 29, 2026 - AI Summary

Financial Performance & Guidance: - GE HealthCare reported Q1 2026 revenue of $5.1 billion, achieving 2.9% organic growth year-over-year. However, adjusted EPS dipped to $0.99, impacted by a $0.16 tariff effect and inflationary pressures. The company has lowered its full-year adjusted EPS guidance to $4.80 - $5.00, reflecting a 5% - 9% growth projection, down from previous expectations.
Inflationary Pressures: - The company faced approximately $250 million in inflation impacts primarily driven by a significant increase in memory chip costs ($100 million) and rising oil and freight costs ($100 million). While actions to offset inflation are expected to mitigate more than half of these costs, Q2 2026 performance is anticipated to decline in the low single digits due to these pressures.
Challenges in Patient Care Solutions (PCS) Segment: - The PCS segment experienced an 8.1% organic revenue decline YOY due to large monitoring installations being concentrated in the second half of the year, alongside anticipated low-margin impacts from the launch of a new premium anesthesia product. Backlog conversion and overall segment performance have been flagged as areas requiring focused improvements.

Exclusive for Stockcircle Pro members

Sign upSign Up
$79.38

Target Price by Analysts

30.9% upsideGE HealthCare Technologies Target Price DetailsTarget Price
$108.05

Current Fair Value

78.2% upside

Undervalued by 78.2% based on the discounted cash flow analysis.

Share Statistics

Market cap$28.02 Billion
Enterprise Value$38.46 Billion
Dividend Yield$0.14 (0.23%)
Earnings per Share$4.56
Beta0.86
Outstanding Shares456,000,000

Return

Return on Equity14.11%ROE
Return on Assets4.05%
Return on Invested Capital7.89%

Valuation & Multiples

P/E Ratio18.66P/E Ratio
PEG-60.15PEG
Price to Sales1.41Price to Sales
Price to Book Ratio2.64Price to Book Ratio
Enterprise Value to Revenue1.93
Enterprise Value to EBIT17.06
Enterprise Value to Net Income25
Total Debt to Enterprise0.33
Debt to Equity1.19Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 6, 2026
EPS Estimate
$1.05
Average shareholder expectation
Revenue Estimate
$5.03 B
Average shareholder expectation

Next Earnings Call

Expected Date
July 29, 2026
EPS Estimate
$1.04
Average shareholder expectation
Revenue Estimate
$5.27 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio1.0412 29.34%
Total Calls2,424,758 14.97%
Total Puts2,524,750 18.39%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %85.18% 10.75%
Total Invested$27.61B 58.66%
Investors Holding1,303 66.00%

ESG Score

No data

About GE HealthCare Technologies Inc

Relevant Senate Committees

Finance

This powerful committee controls taxation, trade, and entitlement spending. It directly impacts GE HealthCare Technologies through policies related to Medicare and Medicaid reimbursement rates, corporate tax policy, and international trade tariffs.

Appropriations

This committee directly allocates discretionary federal spending. Its subcommittees determine the specific funding for agencies and programs (e.g., NIH, VA, Medicare/Medicaid components) that are major customers or influence the market for GE HealthCare Technologies.

Health, Education, Labor, and Pensions

This committee directly regulates the FDA, which is the primary regulatory body for GE HealthCare Technologies' medical devices and diagnostics. It also oversees NIH funding, impacting research relevant to GEHC's innovation pipeline.

Veterans' Affairs

GE HealthCare Technologies manufactures medical devices and solutions that are likely purchased by the Department of Veterans Affairs (VA). The committee's funding decisions directly impact GEHC's potential sales and revenue from the VA healthcare system.